GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biovica International AB (OSTO:BIOVIC B) » Definitions » Cash Ratio

Biovica International AB (OSTO:BIOVIC B) Cash Ratio : 6.77 (As of Jan. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Biovica International AB Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Biovica International AB's Cash Ratio for the quarter that ended in Jan. 2024 was 6.77.

Biovica International AB has a Cash Ratio of 6.77. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Biovica International AB's Cash Ratio or its related term are showing as below:

OSTO:BIOVIC B' s Cash Ratio Range Over the Past 10 Years
Min: 0.11   Med: 6.77   Max: 21.81
Current: 6.77

During the past 9 years, Biovica International AB's highest Cash Ratio was 21.81. The lowest was 0.11. And the median was 6.77.

OSTO:BIOVIC B's Cash Ratio is ranked better than
72.63% of 1476 companies
in the Biotechnology industry
Industry Median: 3.025 vs OSTO:BIOVIC B: 6.77

Biovica International AB Cash Ratio Historical Data

The historical data trend for Biovica International AB's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biovica International AB Cash Ratio Chart

Biovica International AB Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only 2.15 4.50 16.91 5.58 4.84

Biovica International AB Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.09 4.84 4.09 3.13 6.77

Competitive Comparison of Biovica International AB's Cash Ratio

For the Biotechnology subindustry, Biovica International AB's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biovica International AB's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biovica International AB's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Biovica International AB's Cash Ratio falls into.



Biovica International AB Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Biovica International AB's Cash Ratio for the fiscal year that ended in Apr. 2023 is calculated as:

Cash Ratio (A: Apr. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=114.327/23.638
=4.84

Biovica International AB's Cash Ratio for the quarter that ended in Jan. 2024 is calculated as:

Cash Ratio (Q: Jan. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=105.238/15.535
=6.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biovica International AB  (OSTO:BIOVIC B) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Biovica International AB Cash Ratio Related Terms

Thank you for viewing the detailed overview of Biovica International AB's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Biovica International AB (OSTO:BIOVIC B) Business Description

Traded in Other Exchanges
Address
Dag Hammarskjolds vag 54B, Uppsala Science Park, Uppsala, SWE, 752 37
Biovica International AB is a biotech company. It develops and commercializes blood-based diagnostic tests with biomarkers that improve monitoring and evaluation of modern cancer treatments. Through collaboration with world- leading cancer institutes and pharmaceutical companies, it promotes the trend in healthcare for personalized treatment, with a primary focus on patient survival and benefits to society. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.

Biovica International AB (OSTO:BIOVIC B) Headlines

No Headlines